Saturday, July 11, 2026

pharma · Nonalcoholic Steatohepatitis

Tobira Therapeutics

Tobira Therapeutics drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
1
Drugs
2
Patents
0
Intelligence · Drug Pipeline

Tobira Therapeutics pipeline

Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Tobira Therapeutics drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

2 compounds
  1. US regulatory status: approved.

  2. Development asset linked to Tobira Therapeutics in public FDA and regional records.